INNOVATIVE THERAPIES BASED ON A NEXT-GENERATION DRUG DELIVERY PLATFORM

R&D

Anticancer Drug/Personalized Anticancer Drug/Osteoarthritis/COPD/Neurodegenerative Diseases

Osteoarthritis

  • 01
    Knee Osteoarthritis
    Osteoarthritis is the most common form of arthritis. This degenerative condition occurs when the cartilage in the joint and surrounding tissues wears down over time.
    The Korean market of osteoarthritis treatments, including anti-inflammatory drug, hyaluronic acid, knee replacement surgery, physical therapy, and oriental medicine therapy, is projected to reach $1.5B. Knee osteoarthritis patients account for 45% of the disease’s total burden. As of 2016, 2.7M people had knee osteoarthritis in Korea.
    Knee osteoarthritis is a condition with high unmet medical needs and no cure other than joint replacement surgery.
  • 02
    Therapeutics
    Development
    MDimune Inc. is in the process of developing therapeutics for knee osteoarthritis using mesenchymal stem cell-derived vesicles (MSCDVs), which can be readily administered into the knee joint cavity using a syringe.
    The effects of MSCDVs treatment in pain relief and cartilage regeneration were observed in the animal model of osteoarthritis.
    Based on these promising results, an Investigational New Drug (IND) application targeting knee osteoarthritis will be submitted in 2021.